Switching - null sWR [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2010-05-04 16:04 (5886 d 18:27 ago) – Posting: # 5284
Views: 41,634

Dear Dave, dear All,

❝ One thing I was happy about with the FDA progesterone recommendations was that the FDA specified 0.294 for sig_wr, because a few of their previous publications recommended using 0.25, which didn't map close to the 30% intraCV cutoff.


Please note sigmaS=0.294 is only the switching variability i.e. from which on the scaled ABE criterion is allowed if sWR>sigmaS. In their SAS code the regulatory constant s0 is still 0.25.
See f.i. on page 6 and 8 of the progesterone draft guidance:
  theta=((log(1.25)/0.25)**2
(=0.89257422)

This leads to the discontinuity at CV=30% and the inflation of the consumer's risk around CV=30% as described by:
L. Endrenyi and L. Tothfalusi
"Regulatory Conditions for the Determination of Bioequivalence of Highly Variable Drugs"
J. Pharm. Pharmaceut. Sci. (www.cspsCanada.org) 12 (1): 138 - 149, 2009


Edit: online resource added. [Helmut]

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
124 visitors (0 registered, 124 guests [including 21 identified bots]).
Forum time: 10:31 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5